Lubiprostone plus PEG electrolytes versus placebo plus PEG electrolytes for outpatient colonoscopy preparation: a randomized, double-blind placebo-controlled trial
Recommended Citation
Sofi AA, Nawras AT, Pai C, Samuels Q, and Silverman AL. Lubiprostone plus PEG electrolytes versus placebo plus PEG electrolytes for outpatient colonoscopy preparation: a randomized, double-blind placebo-controlled trial. Am J Ther 2015; 22(2):105-110.
Document Type
Article
Publication Date
3-1-2015
Publication Title
American journal of therapeutics
Abstract
Bowel preparation using large volume of polyethylene glycol (PEG) solutions is often poorly tolerated. Therefore, there are ongoing efforts to develop an alternative bowel cleansing regimen that should be equally effective and better tolerated. The aim of this study was to assess the efficacy of lubiprostone (versus placebo) plus PEG as a bowel cleansing preparation for colonoscopy. Our study was a randomized, double-blind placebo-controlled design. Patients scheduled for screening colonoscopy were randomized 1:1 to lubiprostone (group 1) or placebo (group 2) plus 1 gallon of PEG. The primary endpoints were patient's tolerability and endoscopist's evaluation of the preparation quality. The secondary endpoint was to determine any reduction in the amount of PEG consumed in the lubiprostone group compared with the placebo group. One hundred twenty-three patients completed the study and were included in the analysis. There was no difference in overall cleanliness. The volume of PEG was similar in both the groups. The volume of PEG approached significance as a predictor of improved score for both the groups (P = 0.054). Lubiprostone plus PEG was similar to placebo plus PEG in colon cleansing and volume of PEG consumed. The volume of PEG consumed showed a trend toward improving the quality of the colon cleansing.
Medical Subject Headings
Adult; Aged; Aged, 80 and over; Colonoscopy; Double-Blind Method; Electrolytes; Female; Humans; Lubiprostone; Male; Middle Aged; Outpatients; Polyethylene Glycols; Prospective Studies; Solutions; Treatment Outcome
PubMed ID
23846523
Volume
22
Issue
2
First Page
105
Last Page
110